[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624847":3},{"organization":4,"armGroups":7,"interventions":31,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":57,"collaborators":11,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":11,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":11,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":11,"overallStatus":78,"whyStopped":11,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":11},{"fullName":5,"class":6},"Jiangsu Hansoh Pharmaceutical Co., Ltd.","INDUSTRY",[8,15,19,23,27],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1a","EXPERIMENTAL",null,[13,14],"Drug: HS-10504","Drug: SHR-A2102",{"label":16,"type":10,"description":11,"interventionNames":17},"Cohort 1b",[13,18],"Drug: SHR-A2009",{"label":20,"type":10,"description":11,"interventionNames":21},"Cohort 1c",[13,22],"Drug: HS-20122",{"label":24,"type":10,"description":11,"interventionNames":25},"Cohort 1d",[13,26],"Drug: HS-20117",{"label":28,"type":10,"description":11,"interventionNames":29},"Cohort 2",[13,30],"Drug: SHR-1826",[32,37,41,45,49,53],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":11},"DRUG","HS-10504","HS-10504 administered orally every day",[9,16,20,24,28],{"type":33,"name":38,"description":39,"armGroupLabels":40,"otherNames":11},"SHR-A2009","SHR-A2009 administered intravenously",[16],{"type":33,"name":42,"description":43,"armGroupLabels":44,"otherNames":11},"HS-20122","HS-20122 administered intravenously",[20],{"type":33,"name":46,"description":47,"armGroupLabels":48,"otherNames":11},"HS-20117","HS-20117 administered intravenously",[24],{"type":33,"name":50,"description":51,"armGroupLabels":52,"otherNames":11},"SHR-1826","SHR-1826 administered intravenously",[28],{"type":33,"name":54,"description":55,"armGroupLabels":56,"otherNames":11},"SHR-A2102","SHR-A2102 administered intravenously",[9],{"type":58,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100624847","phase-1-a-phase-ib-study-of-hs-10504-combined-therapy-in-nsclc-100624847",false,"NCT07414953","A Phase Ib Study of HS-10504 Combined Therapy in NSCLC","A Phase Ib Study of the Safety, Efficacy, Pharmacokinetics, and Immunogenicity of HS-10504 Combined Therapy in Advanced Non-small Cell Lung Cancer Patients","Inclusion Criteria:\n\n* Cohort1:participants with EGFR mutation advanced stage NSCLC，disease progression on or after prior treatment；\n* Cohort2:participants with MET position advanced stage NSCLC，disease progression on or after prior treatment；\n* With at least 1 target lesion according to RECIST 1.1.\n* Appropriate organ function\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1 and no deterioration within 2 weeks prior to the first dose.\n* Minimum expected survival longer than 12 weeks\n* Female subjects of childbearing potential are willing to take appropriate contraceptive measures and should not breastfeed from signing the informed consent form (ICF) through 6 months after the last dose; male subjects are willing to use barrier contraception (i.e., condom) from signing the ICF through 6 months after the last dose.\n* Voluntarily participate in this clinical trial, understand the study procedures, and be able to sign written informed consent form.\n\nExclusion Criteria:\n\n* Insufficient wash out duration of prior systemic anticancer therapy\n* Local radiotherapy within 2 weeks prior to first dose of investigational drug\n* Pleural\u002Fabdominal effusion requires clinical intervention\n* Major surgery within 4 weeks prior to first dose of investigational drug\n* History of drugs may prolong QT interval\n* Have any grade ≥ 2 residual toxicity according to Common Terminology Criteria for Adverse Events (CTCAE, version 5.0) from prior anti-tumor therapy (except alopecia and residual neurotoxicity).\n* Presence of brain metastasis or carcinomatous meningtitis\n* History of other primary malignancies\n* Significant, uncontrolled, or active cardiovascular diseases\n* Severe or poorly controlled diabetes\n* Extremely obesity or emaciation\n* Clinically significant bleeding symptoms or obvious bleeding tendency within 1 month prior to the first dose\n* Severe arteriovenous thrombotic events (e.g., deep venous thrombosis, pulmonary embolism) within 3 months prior to the first dose\n* Severe infection within 4 weeks\n* History of systemic glucocorticoids over 28 days prior to first dose of investigational drug\n* Presence of known active infectious diseases,\n* Presence of hepatic encephalopathy, Hepantorenal Syndrome\n* Presence or history of confirmed or suspected ILD;\n* Prior history of significant neurological or mental disorders, including conditions that interfere with assessment, such as epilepsy, dementia, or major depressive disorder.\n* Past history of severe allergy, or history of hypersensitivity to any active or inactive ingredient of investigational drugs.\n* Presence of any conditions that jeopardize subject safety or interfere with study assessments as judged by the investigator.","ALL","18 Years","75 Years",{"count":70,"type":71},400,"ESTIMATED","INTERVENTIONAL",[74],"PHASE1","This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-10504 combined therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).",[77],"Lung Cancer","NOT_YET_RECRUITING","2026-02-14",{"date":81,"type":82},"2026-02-17","ACTUAL",{"date":84,"type":71},"2026-03-30",{"date":86,"type":71},"2028-11-30",{"name":5,"class":6}]